In-vitro Antifungal Activity of Some 1,3,5-triazine Derivatives

Introduction The incidence of fungal infections is increasing at an alarming rate, presenting an enormous challenge to healthcare professionals. This increase is directly related to the growing population of immunocompromised individuals, resulting from changes in medical practice such as the use of intensive chemotherapy and immunosuppressive drugs. The most common fungal infections of humans are caused by the Candida, Cryptococcus and Aspergillus species. In addition, gains in many areas of these disease controls are seriously jeopardized by the emergence of drug-resistant clinical isolates to the available drugs. Treatment of deeply invasive infections has consistently lagged behind chemotherapy; new approaches are urgently needed for improved diagnosis, including species identification, rapid and predictive susceptibility assays, and effective treatment. In view of the above and as part of the our ongoing research on electron rich nitrogen heterocycle system comprises 1,3,5-triazine antimicrobials, which is 5-aza-bioisoster of purine is an important pharmacophore and privileged structure in medicinal chemistry,